Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae810 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Mai Kawazoe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo 143-8541, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Bone Density Conservation Agents, Denosumab, Glucocorticoids. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: JSPS.
Abstract (Originalsprache)
Context
Wnt/β-catenin signaling pathway is one of the pathogenic mechanisms of glucocorticoid-induced osteoporosis (GIOP). We previously reported the potential of inhibiting sclerostin as a treatment for GIOP.
Objective
To compare the efficacy of romosozumab (ROMO), a monoclonal antibody against sclerostin, with existing therapy for GIOP.
Methods
Patients with rheumatic diseases who had not previously received treatment for osteoporosis and were newly treated with prednisolone 15 mg/day or more were randomly assigned to receive ROMO, denosumab (DMAb), or bisphosphonates (BP). After the initiation of glucocorticoid therapy, we measured the bone mineral density (BMD) of the lumbar spine, femoral neck, and total hip every 6 months and bone turnover markers every 3 months for 12 months.
Results
Eleven patients were assigned to the ROMO group, 14 to the DMAb group, and 14 to the BP group. The median [25th to 75th percentile] percent change in lumbar spine BMD from baseline at 12 months was the greatest in the ROMO group (ROMO: 8.6 [3.1-12.4]%, DMAb: 3.3 [1.5-6.2]%, BP: −0.4 [−3.4-1.1]%). Among bone formation markers, serum levels of bone alkaline phosphatase were slightly elevated in the ROMO group, whereas those of N-terminal propeptide of type I procollagen and osteocalcin decreased in all 3 groups; however, these changes were smaller in the ROMO group. Serum levels of bone resorption markers and a urine bone quality marker decreased in all groups.
Conclusion
Treatment with ROMO significantly increased lumbar spine BMD in glucocorticoid-treated patients, suggesting that ROMO is effective for GIOP. Clinical trial number UMIN000037239
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo 143-8541, Japan.
- Department of Immunopathology and Immunoregulation, Toho University School of Medicine, Tokyo 143-8541, Japan.
ORCID-Profile: Mai Kawazoe, Kaichi Kaneko, Sei Muraoka, Takahiko Sugihara, Toshihiro Nanki
Förderung
- JSPS
Zitieren
APA
Kawazoe, M., Kaneko, K., Masuoka, S., Yamada, S., Yamada, Z., Muraoka, S., Furukawa, K., Sato, H., Watanabe, E., Koshiba, K., Irita, I., Kanaji, M., Sugihara, T., Nishio, J., & Nanki, T. (2025). Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae810
Vancouver
Kawazoe M, Kaneko K, Masuoka S, Yamada S, Yamada Z, Muraoka S, et al. Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae810
BibTeX
@article{Kawazoe2025,
author = {Kawazoe, Mai and Kaneko, Kaichi and Masuoka, Shotaro and Yamada, Soichi and Yamada, Zento and Muraoka, Sei and Furukawa, Karin and Sato, Hiroshi and Watanabe, Eri and Koshiba, Keiko and Irita, Izumi and Kanaji, Miwa and Sugihara, Takahiko and Nishio, Junko and Nanki, Toshihiro},
title = {Comparison of Efficacy of Romosozumab With Denosumab and Risedronate in Patients Newly Initiating Glucocorticoid Therapy},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae810}
}
EUVIMED